

## Title (en)

THIENO-IMINO ACID DERIVATIVES FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS

## Title (de)

THIENO-IMINOSAURE-DERIVATE ALS INHIBITOREN VON MATRIX-METALLOPROTEINASEN

## Title (fr)

DERIVES DE THIENO-IMINOACIDE EN TANT QU'INHIBITEURS DE METALLOPROTEINASES MATRICIELLES

## Publication

**EP 1723148 A2 20061122 (DE)**

## Application

**EP 05700992 A 20050118**

## Priority

- EP 2005000417 W 20050118
- DE 102004004974 A 20040131

## Abstract (en)

[origin: WO2005073236A2] The invention relates to the compounds of formula (I), which are suitable for producing drugs for the prophylaxis and therapy of diseases, whereby the course thereof involves the increased activity of matrix metalloproteinases. Diseases belonging thereto are degenerative joint diseases, for example, osteo-arthroses, spondyloses, chondroporosis after articulation injury or a long duration of articulation immobilization after meniscus or patella injury or torn ligaments, or a disease of the connective tissue, such as collagenoses, periodontal diseases, problems with healing wounds, or a chronic disease of the locomotor system, such as inflammatory, immunological or metabolic-related acute or chronic arthritides, arthropathies, myalgias or troubles of the bone metabolism, or ulceration, atherosclerosis or stenosis. The compounds of formula (I) are also suitable for treating inflammatory diseases or cancers, metastatic tumors, cachexia, anorexia, heart failure or septic shock and in the prophylaxis of myocardial and cerebral infarction.

## IPC 8 full level

**C07D 495/04** (2006.01); **A61K 31/4365** (2006.01); **A61P 9/10** (2006.01); **A61P 19/00** (2006.01); **A61P 35/00** (2006.01); **C07D 495/00** (2006.01)

## CPC (source: EP US)

**A61P 1/02** (2017.12 - EP); **A61P 1/14** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 17/02** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/04** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 495/04** (2013.01 - EP US)

## Citation (search report)

See references of WO 2005073236A2

## Citation (examination)

WO 9906410 A1 19990211 - AMGEN INC [US]

## Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

## DOCDB simple family (publication)

**WO 2005073236 A2 20050811; WO 2005073236 A3 20060126**; DE 102004004974 A1 20050818; EP 1723148 A2 20061122; JP 2007519654 A 20070719; JP 4733648 B2 20110727; US 2007093482 A1 20070426; US 7399770 B2 20080715

## DOCDB simple family (application)

**EP 2005000417 W 20050118**; DE 102004004974 A 20040131; EP 05700992 A 20050118; JP 2006550004 A 20050118; US 46118906 A 20060731